# Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus

Study · id `cardio:ct-nct07797036` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07797036](<https://clinicaltrials.gov/study/NCT07797036>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07797036

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 226 participants.

## Technical summary

Registry record NCT07797036. Randomized; no masking; primary purpose prevention. Start 2027-09-01 (anticipated); primary completion 2030-09-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 2/3
- Enrolled: 226 participants (planned count; ClinicalTrials.gov record NCT07797036, source copy `cardio:ctgov-nct07797036-2026-09-28`, retrieved 2026-10-26)
- Planned start: 2027-09-01 (anticipated) (ClinicalTrials.gov record NCT07797036, source copy `cardio:ctgov-nct07797036-2026-09-28`, retrieved 2026-10-26)
- Primary completion: 2030-09-01 (anticipated) (ClinicalTrials.gov record NCT07797036, source copy `cardio:ctgov-nct07797036-2026-09-28`, retrieved 2026-10-26)
- Completion: 2030-12-31 (anticipated) (ClinicalTrials.gov record NCT07797036, source copy `cardio:ctgov-nct07797036-2026-09-28`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07797036, source copy `cardio:ctgov-nct07797036-2026-09-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07797036-2026-09-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus
- Condition: Gestational Diabetes Mellitus (GDM)
- Condition: Metabolic Syndrome
- Intervention (Drug): Semaglutide (Wegovy) weekly injection
- Lead sponsor: University of Massachusetts, Worcester
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Metabolic syndrome (`cardio:metabolic-syndrome`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: University of Massachusetts, Worcester (`cardio:org-university-of-massachusetts-worcester`)

## Provenance

Content hash: 56cf97aefc5556ddcc828d8266a7d8a754bd6b7aadee9c769c46ce92044899cf
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
